Down Over Past Year: Can Hims & Hers Stock Rebound?
Hims & Hers Health shares have been hammered, marked by a steep decline over past year. This article breaks down the ...
Biotech
Biotech insights await. This page curates 5 articles on Tempus, Moderna, Praxis, ImmunityBio and market moves to help you evaluate stocks and sharpen your portfolio strategy.
119 articles
Organogenesis (Orgo) 2025 Earnings Outlook and Insights
As investors digest Organogenesis (Orgo) 2025 earnings, the focus shifts to revenue mix, profitability, and upcoming ...
Novocure (NVCR) 2025 Earnings Outlook and Analysis
Novocure faces a pivotal year as TTFields therapy expands and reimbursement pathways evolve. This guide breaks down w...
Musk, Altman, China Fight for Brain Implant Market
A global race to control a nascent $320 billion brain-implant market pits Elon Musk and Sam Altman against Chinese ri...
Rhythm Pharma (RYTM) Earnings: Investors' Key Takeaways
When rhythm pharma (rytm) releases earnings, investors get a window into revenue growth, cash health, and pipeline pr...
RxSight (RXST) 2025 Earnings: What Investors Should Do
RxSight's Q4 2025 earnings report could set the tone for its 2026 trajectory. This guide breaks down the key numbers,...
Revolution Medicines (RVMD) Earnings: Investor Guide
Dive into a practical guide on Revolution Medicines earnings. Learn to parse transcripts, spot the signals that matte...
Acadia (Acad) 2025 Earnings: A Detailed Investor Look
A clear, reader-friendly breakdown of Acadia’s Q4 2025 earnings. We unpack revenue trends, pipeline progress, and key...
Structure Therapeutics Stock Soars: Key Moves and Outlook
Structure Therapeutics stock has surged after a major hedge fund increased its stake. This article breaks down what s...
Lilly Just Took Major Steps Forward in Obesity Drug Market
Two bold moves by Eli Lilly are reshaping the billion-dollar obesity drug market. This guide breaks down what happene...
Recursion (RXRX) 2025 Earnings: Deep Dive Into Strategy
As biotech investors digest Recursion's latest quarterly results, this Deep Dive breaks down what recursion (rxrx) 20...
Iovance Surged This Week on Philadelphia Factory Backbone
Iovance surged this week after robust Q4 results and a Philadelphia manufacturing moat highlighted by a 32 day turnar...